Citations

Clear

116 citation(s) found for "Teng, Li".

Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study
Kijlertsuphasri, Supiya, Moua, Teng , Moua, Teng , Petnak, Tananchai

Mayo Clinic

Thorax | January 22, 2026 | Volume: 81 | Issue: 7 | Pages: 672-678

10.1136/thorax-2025-223803 | PMID 41571308 Get It

Background Antifibrotic (AF) therapy has been shown to potentially reduce the risk of lung cancer (LC) in patients with idiopathic pulmonary fibrosis (IPF). Our study further assesses the impact of AF use and LC incidence in a real-world cohort with patient-level data. Methods A retrospective multisite cohort study involving patients with IPF followed at Mayo Clinic between 2005 and 2022 was conducted. We identified individuals with new diagnoses of LC in the pre-AF and post-AF eras and defined AF use as continuous treatment for 6 months or more before LC diagnosis. Given the inclusion of LC cases prior to the wide availability of AF therapy and potential differences in patients exposed and unexposed to treatment, propensity score analysis with inverse probability of treatment weighting (IPTW) was used to balance comparator groups. Fine and Gray modelling was used to explore risk factors for developing LC, reported as parameter subdistribution HRs (SHR). Results A total of 3313 patients with IPF were included (1161 treated and 2152 non-treated). LC incidence rates were lower for treated patients in the post-AF era (0.34 vs 1.25 per 100 person-years, p<0.001). After IPTW, 2148 treated were compared with 2167 non-treated individuals. AF treatment was independently associated with reduced LC risk (SHR 0.36 (0.16–0.82), p=0.02), while smoking history and higher forced vital capacity were associated with increased risk. Conclusion AF use appears to be associated with a reduced incidence rate and risk of LC in patients with IPF.
Abstract PR036: The TIP60 acetyltransferase complex is a critical dependency in neuroendocrine prostate cancer through its role as a critical coactivator of MYCL downstream of ASCL1
Sun, Zhen, Zhao, Jimmy L. , Ismail, Wazim M., Khan, Zahra, Han, Teng , Young, Serina, Lange, Matthew , Gaspar-Maia, Alexandre, Sawyers, C., Ismail, Wazim, Khan, Zahra F., Nandakumar, Subhiksha , Koche, Richard P , Gaspar‐Maia, Alexandre , Sawyers, Charles L.

Mayo Clinic

Cancer Research | January 20, 2026 | Volume: 86 | Issue: 2_Supplement | Pages: PR036-PR036

10.1158/1538-7445.prostateca26-pr036 Get It

Abstract Neuroendocrine prostate cancer (NEPC) is an increasingly prevalent manifestation of acquired resistance to next generation AR signaling inhibitors (ARSI), that arises via transformation from advanced prostate adenocarcinoma (PRAD) through a mechanism called lineage plasticity. Through characterization of isogenic PRAD and NEPC mouse tumoroid models generated using human-relevant driver mutations (Pten-/-;Rb1-/-;Trp53-/-), we revealed an extensive epigenetic reprogramming in NEPC versus PRAD, particular at enhancers. CRISPR screens focused on TFs and coactivators revealed a NEPC lineage TF survival network comprised of ASCL1, NFIB, SOX1/11, FOXA1/2 and MYCL with exquisite dependency on the TIP60 acetyltransferase complex. During the PRAD-to-NEPC transition, FOXA1, NFIB and TIP60 chromatin binding redistributes to NEPC specific enhancers, resulting in expression of NEPC target genes in a coordinate fashion with ASCL1 functioning as master regulator, culminating in activation of MYCL. MYCL then directly recruits the TIP60 complex to target sites, where it acts as a requisite MYCL coactivator for target gene activation for NEPC growth/survival. The acetyltransferase activity of TIP60 and acetylation of its substrate H2A.Z are both required for NEPC survival, as well as two chromatin reader subunits of the TIP60 complex, BRD8 and YEATS4. Targeted chemical degradation of TIP60 revealed &gt;500-fold dependency in NEPC relative to normal prostate, credentialing the TIP60 complex as a potential therapeutic target in NEPC. Citation Format: Zhen Sun, Jimmy L. Zhao, Wazim M. Ismail, Zahra F. Khan, Teng Han, Subhiksha Nandakumar, Serina Young, Matthew Lange, Richard Koche, Alexandre Gaspar-Maia, Charles L. Sawyers. The TIP60 acetyltransferase complex is a critical dependency in neuroendocrine prostate cancer through its role as a critical coactivator of MYCL downstream of ASCL1 [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Prostate Cancer Research and Treatment; 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(2_Suppl):Abstract nr PR036.
Multi-institutional retrospective study of IDH2-mutated cholangiocarcinoma.
Sahai, Vaibhav , Tran, Nguyen H., Griffith, Kent A. , Peterson, Nicole, Mahipal, A., King, Gentry Teng , Sahai, Vaibhav , Tran, Nguyen H. , Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 567-567

10.1200/jco.2026.44.2_suppl.567 Get It

567 Background: IDH2 mutation is rare (1%) in patients (pts) with cholangiocarcinoma and there are no data on prognosis in these pts and response to first line (1L) chemotherapy or off-label IDH2 inhibitor enasidenib. Methods: This IRB approved retrospective study included consecutive pts 18 years or older with IDH2 mutated biliary cancer identified between 2010-2024 at 4 large academic centers. Pt characteristics, systemic therapy(ies), next-generation sequencing (NGS) and survival data were obtained via review of electronic medical records. Survival probabilities were estimated using the product-limit method of Kaplan-Meier using SAS (v9.4, Cary, NC). Results: In 40 pts who met criteria, 9 (22.5%) underwent curative intent resection/ ablation, 34 (85%) had recurrent or de novo locally advanced or metastatic stage and of them 33 (82.5%) received any therapy for advanced cancer. Of these 33 pts, 25 (75.7%) were female, 29 (87.9%) non-Hispanic White and 32 (97%) had intrahepatic subtype with a median (range) age of 65 (28-82) years. NGS on tissue (51.5%), plasma (21.2%) or both tissue and plasma (27.3%) identified IDH2 R172* in 28 (84.8%), I98T in 1 (3%), F278fs in 1 (3%) pts and not reported/missing in 1 (3%) pt. Most common co-altered genes included TP53 (27.5%), ARID1A (17.5%), PBRM1 (12.5%), CDKN2A (10%), BAP1 (10%). FGFR2 fusion or N/KRAS mutation was present in 2 (5%) pts each. Of 33 pts with advanced stage, 1L therapy was gemcitabine/platinum +/- devimistat or durvalumab in 84.9%. Median (95% CI) progression-free survival (PFS) on 1L chemotherapy and overall survival were 6.6 (4.1-7.8) and 16.3 (12.1-28.9) months, respectively. Eight of 33 (24.2%) pts with advanced stage received off label enasidenib as Nth line therapy with median PFS (95% CI) 3.9 (1.1-5.1) months. Conclusions: Most pts with IDH2 mutation had advanced ds with median survival similar to those with IDH1 mutated advanced cholangiocarcinoma. Off label enasidenib had modest benefit in this rare subset of pts and should be investigated further.
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Shah, Urvi A. , Cogrossi, Laura Lucia , Garcés, Juan‐José , Policastro, Anna , Castro, Francesca , Derkach, Andriy , Fei, Teng , DeWolf, Susan , Grioni, Matteo , Sisti, Sofia , Blaslov, Jenna , Adintori, Peter , McAvoy, Devin , Baichoo, Mirae , Paredes, Jenny , Anuraj, Aishwarya , Pohl, Charlotte , Zinsmeyer, Victoria , Gipson, Brianna , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Block, Torin , Korde, Neha , Tan, Carlyn , Hultcrantz, Malin , Hassoun, Hani , Scordo, Michael , Lahoud, Oscar , Landau, Heather , Peled, Jonathan U. , Chesi, Marta , Mailankody, Sham , D’Souza, Anita , Iyengar, Neil M. , Adintori, Peter A , Hosszu, Kinga K , McAvoy, Devin , Baichoo, Mirae , Cross, Justin R , Paredes, Jenny , Anuraj, Aishwarya , Raj, Sandeep S , Pohl, Charlotte , Zordan, Paola , Zinsmeyer, Victoria , Jesus Faustino Ramos, Ruben J , Lorenzoni, Marco , Gipson, Brianna , Maclachlan, Kylee , Gradissimo, Ana , Boiocchi, Leonardo , Aleynick, Nathan , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Koche, Richard P , Chaligne, Ronan , Block, Torin , Korde, Neha , Tan, Carlyn R , Hultcrantz, Malin , Hassoun, Hani , Shah, Gunjan L , Scordo, Michael , Lahoud, Oscar B , Chung, David J , Landau, Heather , Peled, Jonathan U , Clementi, Nicola , Chesi, Marta , Bergsagel, P. Leif , Mailankody, Sham , Pollak, Michael N , D'Souza, Anita , Landgren, C Ola , Chimonas, Susan , Giralt, Sergio , Usmani, Saad , Iyengar, Neil M , Lesokhin, Alexander M , van den Brink, Marcel R M , Bellone, Matteo , Shah, Urvi A , Derkach, Andriy , Garces, Juan-Jose , Fei, Teng , Maclachlan, Kylee , Aleynick, Nathan , Shah, Gunjan L. , Bergsagel, P. Leif , Pollak, Michaël , Landgren, Ola , Giralt, Sergio , Usmani, Saad Z. , Lesokhin, Alexander M. , Bellone, Matteo

Mayo Clinic

Cancer Discovery | December 4, 2025 | Volume: 16 | Issue: 4 | Pages: 697-720

10.1158/2159-8290.cd-25-1101 | PMID 41342739 Get It

Abstract Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction. See related commentary by Fairfield and Reagan, p. 623
CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2–p53 Axis
Yan, Binyuan, Huang, Mengjun, Wang, Jinxiang , Lei, Hanqi, Tong, Tongyu , Xu, Bin , Cao, Fei, Teng, Qiliang, Mao, Wenjun, Yan, Binyuan , Pang, Jun , Yan, Binyuan , Yan, Binyuan, Huang, Mengjun, Lei, Hanqi, Teng, Qiliang, Huang, Jinsheng , Guan, Yupeng , Mao, Wenjun, Huang, Haojie , Pang, Jun

Mayo Clinic

Research | October 27, 2025 | Volume: 8 | Issue: No issue available | Pages: No page available

10.34133/research.0990 | PMID 41395253 Get It

Prostate cancer (PCa) progression is driven by intricate molecular mechanisms involving dysregulated signaling networks and posttranslational modifications of key regulatory proteins. In this study, we identify a novel oncogenic pathway wherein cyclin-dependent kinase 12 (CDK12) physically interacts with and phosphorylates forkhead box A1 (FOXA1) at serine 234 (S234). Phosphorylation at this residue markedly enhances FOXA1 transcriptional activity, leading to up-regulation of downstream targets including murine double minute 2 (MDM2), a critical negative regulator of the p53 tumor suppressor. Mechanistically, this CDK12–FOXA1–MDM2 axis destabilizes p53, attenuates apoptotic signaling, and promotes PCa cell survival and proliferation. Therapeutic targeting of CDK12 using the small-molecule inhibitor THZ531 or RNA interference effectively abrogates FOXA1 phosphorylation, restores p53 stability, reactivates apoptotic pathways, and suppresses tumor growth. Notably, the identification of S234 as a functional phosphorylation site in FOXA1 reveals a previously uncharacterized posttranslational regulatory mechanism in PCa biology. These findings establish the CDK12–FOXA1–MDM2 axis as a pivotal driver of PCa progression and underscore the therapeutic potential of targeting FOXA1 phosphorylation to restore tumor suppressor function and induce apoptosis in PCa. Our work provides a mechanistic framework for developing precision therapies aimed at disrupting this oncogenic cascade in PCa.
Sirolimus for Venous Malformations: A Systematic Review of Efficacy and Safety
Teng, Joyce , Martini, Jeffrey, Tollefson, Megha M. , Martini, Jeff , Kelly, Michael , Greer, Alexander

Mayo Clinic

Lymphatic Research and Biology | October 7, 2025 | Volume: 23 | Issue: 6 | Pages: 311-319

10.1177/15578585251377562 | PMID 40928941 Get It

Background: Venous malformations can cause substantial morbidity and long-term complications. There are no Food and Drug Administration (FDA)-approved therapies for the treatment of venous malformations. However, off-label use of sirolimus has demonstrated clinical benefit in these patients. This systematic review evaluates the efficacy and safety of sirolimus in the management of venous malformations. Methods and Results: A systematic literature search identified 26 studies comprising 98 patients treated with sirolimus for venous malformations. Most studies were case reports or case series (77%), with 15% prospective trials and 8% retrospective analyses. Sirolimus, primarily administered orally, yielded some level of clinical improvement in 72% of reported patients, with consistent symptomatic relief observed in coagulopathy, bleeding, anemia, pain, and improved function. However, reduction in the size of the malformation varied and treatment-limiting side effects were observed. Conclusions: Oral sirolimus is a promising treatment option for venous malformations, especially for those with deep venous malformations. A direct, targeted topical treatment could provide clinical benefit for the cutaneous manifestation without the risk of off-target effects as occur with oral sirolimus. Further prospective, controlled studies are warranted to elucidate sirolimus’s role in managing venous malformations.
Home-based pulmonary rehabilitation and health coaching in fibrotic interstitial lung disease: a perspective on current evidence and future directions
Moua, Teng , Benzo, Roberto

Mayo Clinic

Expert Review of Respiratory Medicine | July 24, 2025 | Volume: 20 | Issue: 2 | Pages: 121-131

10.1080/17476348.2025.2539540 | PMID 40703055 Get It

Impact of Home-Based Pulmonary Rehabilitation in Fibrotic Interstitial Lung Disease
Roy, M., Moua, Teng , Moon, Ji‐Yong , Roy, M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7292-A7292

10.1164/ajrccm.2025.211.abstracts.a7292 Get It

Abstract Rationale: Fibrotic interstitial lung diseases (f-ILDs) often lead to increased dyspnea and decreased physical activity, negatively impacting patient quality of life. While center-based pulmonary rehabilitation (PR) provides known benefits, access and adherence may be limited. This study investigates the implementation of a home-based pulmonary rehabilitation program with telephonic health coaching to improve physical activity and respiratory-related quality of life (RR-QOL) over 12 weeks. Methods: This prospective, single-center, non-randomized study enrolled patients with various f-ILD subtypes and severities over two years. Participants engaged in video-based exercises (25 minutes/day, 6 days per week) with weekly telephonic health coaching. Primary outcomes included changes in average daily steps, dyspnea (modified Medical Research Council (mMRC)), and self-reported RR-QOL (Chronic Respiratory Questionnaire (CRQ)- Physical and Emotional Summary domain scores). Minimal Clinically Important Differences (MCID) for study endpoints were defined as ≥600 steps per day, 1-point change in mMRC, and 0.5-point change in CRQ Physical and Emotional Summary scores, used to stratify patient responses to intervention as improved, stable, or worsened. Pre- and post-intervention summary results were compared using paired two-sample t-tests. The percentage of patients reaching MCID thresholds for improvement in primary endpoints was also reported. Results: 88 patients completed the program (mean age 70.2 years, 54% male, and mean FVC 66.9%). Mean CRQ Physical Summary scores improved from baseline 4.09 to 4.35 (mean improvement of 0.26 with 95% CI [0.06, 0.46]). 35% of patients achieved MCID change in the CRQ Physical Summary score, 34% in the CRQ Emotional score, and 22% in mMRC. Although 24% of patients increased their daily steps by 600 or more, average daily steps declined from 7,594 to 7,103 (mean decrease of 492 with 95% CI [101, 883]). When stratified by outcome responses to intervention (improved, stable, or worsened), lower baseline DLCO% was associated with decreased CRQ Physical Summary Scores and daily steps. Conclusion: Home-based PR may improve self-reported quality of life in f-ILD patients, as evidenced by improved CRQ Physical Summary scores. DLCO% may be associated with poorer response to PR intervention, as lower values were associated with declines in CRQ Physical Summary scores and daily steps. These findings support the potential utility of home-based rehabilitation and customizing individual strategies according to baseline characteristics and background disease progression.
Serum Inflammatory Markers as Predictors of Therapeutic Response to Anti-inflammatory Therapy in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
Kluanwan, Yanisa , Moua, Teng

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5347-A5347

10.1164/ajrccm.2025.211.abstracts.a5347 Get It

Abstract RATIONALE: Pulmonary fibrosis is recognized as the end result of multiple and recurrent pathways of lung injury. However, the role of chronic inflammation in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease (non-IPF f-ILD) remains inconclusive, as acute responses to anti-inflammatory treatment may vary. A reliable predictor for identifying patients who stand to benefit from treatment may be helpful for improving or sustaining lung function and avoiding adverse treatment effects. Our study aims to assess whether initial serum inflammatory markers, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), in the absence of clinically suspected infection or other causes of inflammation, are predictive of therapeutic response to anti-inflammatory medications in non-IPF f-ILD. METHODS: We performed a retrospective study comparing treatment response to anti-inflammatory therapy in non-IPF f-ILD stratified by initial CRP or ESR levels. Treatment was defined as corticosteroid or steroid-sparing agent for three months or more with lung function response defined as: 1) relative increase in percent predicted forced vital capacity (FVC%) &gt; 5% in 6 months or &gt; 10% or greater in 12 months; or 2) no change or any increase in FVC% if FVC% was declining prior to treatment initiation (relative decline in FVC% &gt; 5% in the prior 6 months or &gt; 10% in the prior 12 months). Logistic regression was used to predict treatment response as stratified by high vs low-to-normal inflammatory markers, with a mixed model for repeated measures for comparing FVC% change while treated. RESULTS: One hundred sixty-seven non-IPF f-ILD pts received anti-inflammatory therapy with baseline inflammatory markers stratified by high (N = 104) vs low-to-normal (N = 63) prior to treatment. Median age was 64 years with systemic rheumatic disease diagnosed in 58%. Treatment response was higher in patients with elevated inflammatory markers (55.77% vs. 34.92%, P = 0.011), even after adjustment for age, sex, baseline FVC%, and treatment duration (OR 2.45 [1.243-4.828], P = 0.010). FVC% slope from treatment initiation to discontinuation appeared to be increasing in patients with higher baseline inflammatory markers compared to those with low to normal marker levels (P = 0.003) (Figure1). CONCLUSION: Patients with non-IPF f-ILD and high initial inflammatory markers appear to be more acutely responsive to anti-inflammatory therapy with slower FVC decline or improvement over time while on treatment. These findings suggest baseline serum CRP and ESR may be reliable predictors of treatment response and direct treatment duration and intensity for efficacy or reducing adverse effects.
302. A Randomized Controlled Trial of Rapid Pathogen and Resistance Identification from Positive Blood Cultures
Teng, Christine B. , Hon, Pei Yun, Teng, Regina SH, Yap, Min Yi , Wee, Sharon , Chia, Jonathan, Mendis, Shehara M, Izharuddin, Ezlyn, Lin, Ray JH, Sim, Rees Chin Swee, Kang, Charlene MZ, Banerjee, Ritu , De, Partha Pratim, Vasoo, Shawn , Teng, Regina SH, Chia, Jonathan, Lin, Ray JH, Chia, Po Ying , Kang, Charlene MZ, Chen, Mark , Chow, Angela , Yoong, Joanne , Lye, David Chien , Patel, Robin , Tambyah, Paul Anantharajah

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.092 Get It

Abstract Background Morbidity from bacteremia may be exacerbated by inadequate initial antibiotic therapy. This concern however may lead to hesitance to de-escalate while awaiting pathogen identification and susceptibility results. We performed a randomized controlled trial evaluating the impact of a strategy for rapid pathogen and resistance detection directly from positive blood culture bottles (BCBs) using a rapid multiplex PCR (rmPCR) complemented with a rapid phenotypic screen (RPS) for extended-spectrum beta-lactamases and carbapenemases in a setting with moderate to high levels of antimicrobial resistance where routine direct-from-BCB disk diffusion susceptibility testing was in place Methods Patients with positive BCBs were randomized to 2 arms: 1) Standard BCB processing (including direct from BCB disk diffusion susceptibility testing - control, n=419) with antimicrobial stewardship (AS); or 2) rmPCR/RPS with AS (rmPCR/RPS, n=425). The primary outcome was time from positive blood culture result to prescription of an effective or optimal antibiotic regimen. An effective antibiotic regimen was defined as one active against the detected pathogen(s); an optimal antibiotic regimen was defined as an effective regimen which was also the most narrow spectrum and targeted one, as recommended by institutional guidelines. Mortality was analyzed as a secondary outcome. Results True bacteremia was identified in 658 patients (n=329 in both arms); 597 were monomicrobial (405 with aerobic or facultative anaerobic Gram negatives rods [AGNR]) and 61 polymicrobial (41 harboring AGNR). Time from BCB Gram stain to prescription of an effective antibiotic was 9.9 versus 3.2 hours in the control and rmPCR/RPS groups, respectively (p=0.58) and time from Gram stain to prescription of an optimal antibiotic regimen was 41.6 versus 29.4 hours in the two groups, respectively (p &lt; 0.001). 14-day mortality was 7.6% versus 4.3% (p = 0.069) and 30-day mortality was 11.2% versus 8.8% (p=0.30) in the two groups, respectively. Conclusion Compared to control methods which included direct-from-BCB disk diffusion susceptibility testing, an intervention comprising rmPCR/RPS with AS applied to positive blood cultures improved time to optimal therapy but not time to effective therapy or mortality. Disclosures Shawn Vasoo, MBBS, MRCP, D(ABP), D(ABIM) (Inf Dis), FRCPath, bioMerieux: In-kind, for this study|Rosco Diagnostica: In-kind, for this study Robin Patel, MD, a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, a: See above|MicuRx Pharmaceuticals and BIOFIRE: Grant/Research Support|PhAST, Day Zero Diagnostics, Abbott Laboratories, Sysmex, DEEPULL DIAGNOSTICS, S.L., Netflix, Oxford Nanopore Technologies and CARB-X: Advisor/Consultant|Up-to-Date and the Infectious Diseases Board Review Course.: Honoraria Paul Tambyah, MBBS (S'pore), Diplomate, American Board of Internal Medicine and Infectious Diseases, Moderna: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support